It is very uncertain whether methotrexate + sulfasalazine changes maintenance of Remission compared with sulfasalazine (very low certainty).
It is very uncertain whether 6‐Mercaptopurine changes failure to maintain remission compared with methotrexate (very low certainty).
Azathioprine or 6‐mercaptopurine showed no clear difference in clinical remission1 compared with methotrexate (low certainty).
Azathioprine or 6‐mercaptopurine may leads to lower adverse events compared with methotrexate (low certainty).
It is very uncertain whether azathioprine or 6‐mercaptopurine changes withdrawals due to adverse events compared with methotrexate (very low certainty).
It is very uncertain whether 6‐Mercaptopurine changes maintenance of remission compared with methotrexate (very low certainty).
It is very uncertain whether 6‐Mercaptopurine changes adverse events compared with methotrexate (very low certainty).
It is very uncertain whether 6‐Mercaptopurine changes withdrawals due to adverse events compared with methotrexate (very low certainty).
It is very uncertain whether 6‐Mercaptopurine changes serious adverse events compared with methotrexate (very low certainty).